Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Echo Therapeutics Inc    

ECHO THERAPEUTICS INC
Mes dernières consult.
Most popular
  Report  
SummaryChartsNewsCalendarCompanyFinancials 
News SummaryMost relevantAll newsSector newsTweets
The feature you requested does not exist. However, we suggest the following feature:

Echo Therapeutics, Inc. (OTCMKTS:ECTE) Files An 8-K Other Events

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/21/2017 | 09:26pm CET

Echo Therapeutics, Inc. (OTCMKTS:ECTE) Files An 8-K Other EventsItem 8.01

Other Events.
As previously reported, due to the financial condition of Echo Therapeutics, Inc. (the “Company”), the Company was unable to make payment on $1,787,000 of the 10% senior secured convertible notes of the Company due on January 28, 2017 (the “January Notes”). An additional $3,361,620 in principal amount of 10% senior secured convertible notes of the Company matures on May 3, 2017 (the “May Notes” and together with the January Notes, the “Notes”). The Company has been engaged in prolonged discussions to obtain new financing and obtain appropriate forbearance and/or waivers from the investors holding Notes. To date, the Company has been unsuccessful in raising financing and, while the Investors have not taken any action against the Company, the Company has not yet received any formal forbearance and/or waiver from the Investors. The Company has been forced to reduce its staff down to one employee, Alan Schoenbart, the Company’s Chief Executive and Chief Financial Officer, who has been working without pay. Further, the Company has been unable to pay rent at its corporate and research facilities, which will more than likely result shortly in eviction proceedings. Additionally, the Company’s patents are at risk. While the Company continues to pursue financing, there can be no assurance that it will be able to do so on acceptable terms or at all, which may result in foreclosure upon the assets of the Company by the Investors.
About Echo Therapeutics, Inc. (OTCMKTS:ECTE)
Echo Therapeutics, Inc. is a medical device company. The Company is engaged in developing a non-invasive, wireless continuous glucose monitoring (CGM) system with use in the wearable-health consumer market, diabetes outpatient market and in the hospital setting. The Company operates through the development of transdermal skin permeation and diagnostic medical devices segment. The Company has also developed its needle-free skin preparation device as a platform technology that allows for enhanced skin permeation enabling extraction of analytes, such as glucose, enhanced delivery of topical pharmaceuticals and other applications. The CGM System includes a skin preparation device, transdermal glucose sensor, battery and wireless transmitter. The Company has conducted several human feasibility clinical studies with its CGM System in healthy subjects, diabetics and critically ill patients, as well as a clinical study at several hospitals in the United States. Echo Therapeutics, Inc. (OTCMKTS:ECTE) Recent Trading Information
Echo Therapeutics, Inc. (OTCMKTS:ECTE) closed its last trading session down -0.0005 at 0.0900 with 313,339 shares trading hands.

The post Echo Therapeutics, Inc. (OTCMKTS:ECTE) Files An 8-K Other Events appeared first on Market Exclusive.

© Market Exclusive 2017, source Market Exclusive

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ECHO THERAPEUTICS INC
2017ECHO THERAPEUTICS, INC. (OTCMKTS : ECTE) Files An 8-K Other Events
AQ
2017ECHO THERAPEUTICS, INC. (OTCMKTS : ECTE) Files An 8-K Departure of Directors or ..
AQ
2017ECHO THERAPEUTICS : Patent Issued for Skin Permeation Device for Analyte Sensing..
AQ
2016ECHO THERAPEUTICS : Announces Second Quarter 2016 Financial Results
PU
2016ECHO THERAPEUTICS : Begins Testing of NextGen CGM System Components
PU
2016ECHO THERAPEUTICS : Announces Institutional Review Board (IRB) Approval of New P..
PU
2016ECHO THERAPEUTICS : Announces Final Closing of Private Placement of $5.1 Million..
PU
2016ECHO THERAPEUTICS : Announces Voting Results of Special Meeting of Stockholders
PU
2016ECHO THERAPEUTICS : Announces New Patents for Non-Invasive Sensing Technology
PU
2015ECHO THERAPEUTICS : Announces Third Quarter 2015 Financial Results and Provides ..
PU
More news
News from SeekingAlpha
2017Echo Therapeutics in a bind over high-cost debt 
2016District court rules in favor of Echo Therapeutics 
2016Echo Therapeutics target of whistleblower suit, survival at stake; shares dow.. 
2016Echo Therapeutics auditor quits; shares down 14% 
2016Echo Therapeutics reports Q2 results 
Chart ECHO THERAPEUTICS INC
Duration : Period :
Echo Therapeutics Inc Technical Analysis Chart | US27876L2060 | 4-Traders
Income Statement Evolution
Managers
NameTitle
Alan Wayne Schoenbart Chief Executive Officer, CFO, Secretary & Director
Christine H. Olimpio Director-Investor Relations & Communications
Sector and Competitors
1st jan.Capitalization (M$)
ECHO THERAPEUTICS INC-72.22%0
THERMO FISHER SCIENTIFIC9.71%83 531
DANAHER3.53%66 848
INTUITIVE SURGICAL12.32%45 927
BOSTON SCIENTIFIC CORPORATION8.15%37 200
ROYAL PHILIPS-1.49%36 661